MCL1 and acute lymphoblastic leukemia: FBXW7 activation or MCL1 deregulation has been found to revive the sensitivity of T‐ALL cell to ABT‐737, thereby positioning MCL1 as a therapeutically important bypass survival protein that empowers FBXW7‐deficient cells to evade apoptosis.